These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 24518162)

  • 1. Pharmacokinetics of raltegravir in the semen of HIV-infected men.
    Antoniou T; Loutfy MR; Brunetta J; Smith G; Halpenny R; la Porte C
    Antivir Ther; 2014; 19(6):607-11. PubMed ID: 24518162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration.
    Fayet Mello A; Buclin T; Franc C; Colombo S; Cruchon S; Guignard N; Biollaz J; Telenti A; Decosterd LA; Cavassini M
    J Antimicrob Chemother; 2011 Jul; 66(7):1573-81. PubMed ID: 21508009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects.
    Cattaneo D; Gervasoni C; Meraviglia P; Landonio S; Fucile S; Cozzi V; Baldelli S; Pellegrini M; Galli M; Clementi E
    J Antimicrob Chemother; 2012 Feb; 67(2):460-4. PubMed ID: 22127581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of raltegravir intensification on HIV proviral DNA in the blood and gut mucosa of men on long-term therapy: a randomized controlled trial.
    Chege D; Kovacs C; la Porte C; Ostrowski M; Raboud J; Su D; Kandel G; Brunetta J; Kim CJ; Sheth PM; Kaul R; Loutfy MR
    AIDS; 2012 Jan; 26(2):167-74. PubMed ID: 22089379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS-163 ETRAL Study.
    Lê MP; Valantin MA; Assoumou L; Soulie C; Le Mestre S; Weiss L; Yazdanpanah Y; Molina JM; Bouchaud O; Raffi F; Reynes J; Calvez V; Marcelin AG; Costagliola D; Katlama C; Peytavin G;
    Pharmacotherapy; 2019 Apr; 39(4):514-520. PubMed ID: 30815916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic study of raltegravir in HIV-infected patients with end-stage liver disease: the LIVERAL-ANRS 148 study.
    Barau C; Braun J; Vincent C; Haim-Boukobza S; Molina JM; Miailhes P; Fournier I; Aboulker JP; Vittecoq D; Duclos-Vallée JC; Taburet AM; Teicher E;
    Clin Infect Dis; 2014 Oct; 59(8):1177-84. PubMed ID: 24992955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Penetration and antiviral efficacy of total and unbound maraviroc, raltegravir and rilpivirine in both female and male genital fluids from HIV-positive patients receiving regimens containing these antiretrovirals.
    Lê MP; Belarbi L; Chaix ML; Dulioust E; Mahjoub N; Salmon D; Viard JP; Duvivier C; Peytavin G; Launay O; Ghosn J
    J Antimicrob Chemother; 2017 Nov; 72(11):3167-3171. PubMed ID: 28961979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Penetration of didanosine in semen of HIV-1-infected men.
    Cruciani M; Liuzzi G; Chirianni A; Audagnotto S; Bonora S; Di Biagio A; Sinicco A; Bassetti M; Gatti G
    J Antimicrob Chemother; 2006 Jun; 57(6):1244-7. PubMed ID: 16556633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High concentration of raltegravir in semen of HIV-infected men: results from a substudy of the EASIER-ANRS 138 trial.
    Barau C; Delaugerre C; Braun J; de Castro N; Furlan V; Charreau I; Gérard L; Lascoux-Combe C; Molina JM; Taburet AM
    Antimicrob Agents Chemother; 2010 Feb; 54(2):937-9. PubMed ID: 19995925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis.
    Calcagno A; Cusato J; Simiele M; Motta I; Audagnotto S; Bracchi M; D'Avolio A; Di Perri G; Bonora S
    J Antimicrob Chemother; 2014 Jan; 69(1):241-5. PubMed ID: 23975735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Creatine kinase elevation in HIV-1-infected patients receiving raltegravir-containing antiretroviral therapy: a cohort study.
    Monteiro P; Perez I; Pich J; Gatell JM; Martínez E
    J Antimicrob Chemother; 2013 Feb; 68(2):404-8. PubMed ID: 23109185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and pharmacokinetics of the combination of etravirine plus raltegravir as novel dual antiretroviral maintenance regimen in HIV-infected patients.
    Casado JL; Bañón S; Rodriguez MA; Moreno A; Moreno S
    Antiviral Res; 2015 Jan; 113():103-6. PubMed ID: 25460844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of the combination raltegravir/atazanavir in HIV-1-infected patients.
    Jansen A; Colbers EP; van der Ven AJ; Richter C; Rockstroh JK; Wasmuth JC; van Luin M; Burger DM
    HIV Med; 2013 Aug; 14(7):449-52. PubMed ID: 23506243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of HIV infection and menopause status on raltegravir pharmacokinetics in the blood and genital tract.
    Cottrell ML; Patterson KB; Prince HM; Jones A; White N; Wang R; Kashuba AD
    Antivir Ther; 2015; 20(8):795-803. PubMed ID: 26040011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of raltegravir on the total and unintegrated proviral HIV DNA during raltegravir-based HAART.
    Nicastri E; Tommasi C; Abbate I; Bonora S; Tempestilli M; Bellagamba R; Viscione M; Rozera G; Gallo AL; Ivanovic J; Amendola A; Pucillo L; Di Perri G; Capobianchi MR; Narciso P
    Antivir Ther; 2011; 16(6):797-803. PubMed ID: 21900711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study.
    Llibre JM; Buzón MJ; Massanella M; Esteve A; Dahl V; Puertas MC; Domingo P; Gatell JM; Larrouse M; Gutierrez M; Palmer S; Stevenson M; Blanco J; Martinez-Picado J; Clotet B
    Antivir Ther; 2012; 17(2):355-64. PubMed ID: 22290239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nucleoside analogues achieve high concentrations in seminal plasma: relationship between drug concentration and virus burden.
    Pereira AS; Kashuba AD; Fiscus SA; Hall JE; Tidwell RR; Troiani L; Dunn JA; Eron JJ; Cohen MS
    J Infect Dis; 1999 Dec; 180(6):2039-43. PubMed ID: 10558966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discordance in HIV-1 viral loads and antiretroviral drug concentrations comparing semen and blood plasma.
    Lorello G; la Porte C; Pilon R; Zhang G; Karnauchow T; MacPherson P
    HIV Med; 2009 Oct; 10(9):548-54. PubMed ID: 19515092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emtricitabine seminal plasma and blood plasma population pharmacokinetics in HIV-infected men in the EVARIST ANRS-EP 49 study.
    Valade E; Tréluyer JM; Illamola SM; Bouazza N; Foissac F; De Sousa Mendes M; Lui G; Chenevier-Gobeaux C; Suzan-Monti M; Rouzioux C; Assoumou L; Viard JP; Hirt D; Urien S; Ghosn J;
    Antimicrob Agents Chemother; 2015 Nov; 59(11):6800-6. PubMed ID: 26282407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption.
    Canducci F; Barda B; Ceresola E; Spagnuolo V; Sampaolo M; Boeri E; Nozza S; Cossarin F; Galli A; Gianotti N; Castagna A; Lazzarin A; Clementi M
    Clin Microbiol Infect; 2011 Jun; 17(6):928-34. PubMed ID: 20854427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.